205 related articles for article (PubMed ID: 32385243)
1. p85β regulates autophagic degradation of AXL to activate oncogenic signaling.
Rao L; Mak VCY; Zhou Y; Zhang D; Li X; Fung CCY; Sharma R; Gu C; Lu Y; Tipoe GL; Cheung ANY; Mills GB; Cheung LWT
Nat Commun; 2020 May; 11(1):2291. PubMed ID: 32385243
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer.
Song X; Akasaka H; Wang H; Abbasgholizadeh R; Shin JH; Zang F; Chen J; Logsdon CD; Maitra A; Bean AJ; Wang H
J Biol Chem; 2020 Feb; 295(8):2348-2358. PubMed ID: 31959629
[TBL] [Abstract][Full Text] [Related]
3. FBXL2- and PTPL1-mediated degradation of p110-free p85β regulatory subunit controls the PI(3)K signalling cascade.
Kuchay S; Duan S; Schenkein E; Peschiaroli A; Saraf A; Florens L; Washburn MP; Pagano M
Nat Cell Biol; 2013 May; 15(5):472-80. PubMed ID: 23604317
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism of 17-allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL receptor tyrosine kinase degradation.
Krishnamoorthy GP; Guida T; Alfano L; Avilla E; Santoro M; Carlomagno F; Melillo RM
J Biol Chem; 2013 Jun; 288(24):17481-94. PubMed ID: 23629654
[TBL] [Abstract][Full Text] [Related]
5. Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis.
Lee WP; Wen Y; Varnum B; Hung MC
Oncogene; 2002 Jan; 21(3):329-36. PubMed ID: 11821945
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism.
Huang JS; Cho CY; Hong CC; Yan MD; Hsieh MC; Lay JD; Lai GM; Cheng AL; Chuang SE
Free Radic Biol Med; 2013 Dec; 65():1246-1256. PubMed ID: 24064382
[TBL] [Abstract][Full Text] [Related]
7. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY
Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839
[TBL] [Abstract][Full Text] [Related]
8. AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.
de Polo A; Luo Z; Gerarduzzi C; Chen X; Little JB; Yuan ZM
J Mol Cell Biol; 2017 Apr; 9(2):154-165. PubMed ID: 27927748
[TBL] [Abstract][Full Text] [Related]
9. Blockade of Axl signaling ameliorates HPV16E6-mediated tumorigenecity of cervical cancer.
Lee EH; Ji KY; Kim EM; Kim SM; Song HW; Choi HR; Chung BY; Choi HJ; Bai HW; Kang HS
Sci Rep; 2017 Jul; 7(1):5759. PubMed ID: 28720772
[TBL] [Abstract][Full Text] [Related]
10. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
Mackiewicz M; Huppi K; Pitt JJ; Dorsey TH; Ambs S; Caplen NJ
Breast Cancer Res Treat; 2011 Nov; 130(2):663-79. PubMed ID: 21814748
[TBL] [Abstract][Full Text] [Related]
11. Ganoderic Acid A Promotes Amyloid-β Clearance (In Vitro) and Ameliorates Cognitive Deficiency in Alzheimer's Disease (Mouse Model) through Autophagy Induced by Activating Axl.
Qi LF; Liu S; Liu YC; Li P; Xu X
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34074054
[TBL] [Abstract][Full Text] [Related]
12. AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival.
Salian-Mehta S; Xu M; Wierman ME
Mol Cell Endocrinol; 2013 Jul; 374(1-2):92-100. PubMed ID: 23648337
[TBL] [Abstract][Full Text] [Related]
13. The tumour suppressor OPCML promotes AXL inactivation by the phosphatase PTPRG in ovarian cancer.
Antony J; Zanini E; Kelly Z; Tan TZ; Karali E; Alomary M; Jung Y; Nixon K; Cunnea P; Fotopoulou C; Paterson A; Roy-Nawathe S; Mills GB; Huang RY; Thiery JP; Gabra H; Recchi C
EMBO Rep; 2018 Aug; 19(8):. PubMed ID: 29907679
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of GSK3β and activation of NF-κB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma.
Paccez JD; Duncan K; Vava A; Correa RG; Libermann TA; Parker MI; Zerbini LF
Mol Biol Cell; 2015 Mar; 26(5):821-31. PubMed ID: 25568334
[TBL] [Abstract][Full Text] [Related]
15. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
16. RET/PTC (rearranged in transformation/papillary thyroid carcinomas) tyrosine kinase phosphorylates and activates phosphoinositide-dependent kinase 1 (PDK1): an alternative phosphatidylinositol 3-kinase-independent pathway to activate PDK1.
Kim DW; Hwang JH; Suh JM; Kim H; Song JH; Hwang ES; Hwang IY; Park KC; Chung HK; Kim JM; Park J; Hemmings BA; Shong M
Mol Endocrinol; 2003 Jul; 17(7):1382-94. PubMed ID: 12738763
[TBL] [Abstract][Full Text] [Related]
17. Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival.
Ammoun S; Provenzano L; Zhou L; Barczyk M; Evans K; Hilton DA; Hafizi S; Hanemann CO
Oncogene; 2014 Jan; 33(3):336-46. PubMed ID: 23318455
[TBL] [Abstract][Full Text] [Related]
18. Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer.
Sen T; Tong P; Diao L; Li L; Fan Y; Hoff J; Heymach JV; Wang J; Byers LA
Clin Cancer Res; 2017 Oct; 23(20):6239-6253. PubMed ID: 28698200
[No Abstract] [Full Text] [Related]
19. Gas6 attenuates lipopolysaccharide‑induced TNF‑α expression and apoptosis in H9C2 cells through NF‑κB and MAPK inhibition via the Axl/PI3K/Akt pathway.
Li M; Ye J; Zhao G; Hong G; Hu X; Cao K; Wu Y; Lu Z
Int J Mol Med; 2019 Sep; 44(3):982-994. PubMed ID: 31524235
[TBL] [Abstract][Full Text] [Related]
20. Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation.
Lauter M; Weber A; Torka R
Cell Commun Signal; 2019 Jun; 17(1):59. PubMed ID: 31171001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
